source
- ARPA-H awards $160 M to accelerate bespoke gene‑editing therapies for rare diseasesARPA-H announced a $160 million, five‑year investment through its THRIVE program to speed the development of personalized gene‑editing treatments for rare genetic conditions. The awardees include…
- FDA rejects Hengrui-Elevar liver cancer drug combo for third time over manufacturing issuesFDA has again turned down a liver cancer drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. This is the third rejection in roughly two years, with the agency citing per…